UroGen Pharma Ltd [NASDAQ: URGN] traded at a low on Wednesday, posting a -44.69 loss after which it closed the day’ session at $4.17.
The results of the trading session contributed to over 9659342 shares changing hands. Over the past one week, the price volatility of UroGen Pharma Ltd stands at 19.42% while the volatility over the past one month is 11.98%.
The market cap for URGN stock reached $192.27 million, with 46.10 million shares outstanding and 38.22 million shares in the current float. Compared to the average trading volume of 796.68K shares, URGN reached a trading volume of 9659342 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about UroGen Pharma Ltd [URGN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for URGN shares is $32.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on URGN stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Scotiabank have made an estimate for UroGen Pharma Ltd shares, keeping their opinion on the stock as Sector Outperform, with their previous recommendation back on April 16, 2025. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on February 19, 2025, representing the official price target for UroGen Pharma Ltd stock. Previously, the target price had yet another raise to $40, while Guggenheim analysts kept a Buy rating on URGN stock. On February 08, 2023, analysts decreased their price target for URGN shares from 35 to 10.
The Average True Range (ATR) for UroGen Pharma Ltd is set at 1.34, with the Price to Sales ratio for URGN stock in the period of the last 12 months amounting to 2.09.
How has URGN stock performed recently?
UroGen Pharma Ltd [URGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -57.75. With this latest performance, URGN shares dropped by -58.51% in over the last four-week period, additionally sinking by -62.73% over the last 6 months – not to mention a drop of -68.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for URGN stock in for the last two-week period is set at 24.48, with the RSI for the last a single of trading hit 19.16, and the three-weeks RSI is set at 28.36 for UroGen Pharma Ltd [URGN]. The present Moving Average for the last 50 days of trading for this stock 10.39, while it was recorded at 7.37 for the last single week of trading, and 11.62 for the last 200 days.
UroGen Pharma Ltd [URGN]: Deeper insight into the fundamentals
UroGen Pharma Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.47 and a Current Ratio set at 5.65.
Insider trade positions for UroGen Pharma Ltd [URGN]
The top three institutional holders of URGN stocks are: RTW INVESTMENTS, LP with ownership of 3.56 million shares, which is approximately 9.661%. ADAGE CAPITAL PARTNERS GP, L.L.C., holding 3.3 million shares of the stock with an approximate value of $$55.37 million in URGN stocks shares; and ADAGE CAPITAL PARTNERS GP, L.L.C., currently with $$51.74 million in URGN stock with ownership which is approximately 8.3739%.
